Clinically, the most advanced of these BH3 mimetics is venetoclax, a selective inhibitor of BCL2, which has received approval by many regulatory authorities worldwide for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [5, 6]. This evidence concerns the gene BCL2 and acute myeloid leukemia.